Showing 4721-4730 of 5623 results for "".
- Independent, Smaller Hospitals Will Need to Make Tough Choices to Survive COVID-19 Financial Crisis: Analysishttps://modernod.com/news/independent-smaller-hospitals-will-need-to-make-tough-choices-to-survive-covid-19-financial-crisis-analysis/2478252/Independent hospitals could need to make drastic decisions such as reducing service lines or workforces to survive the cash crisis caused by the COVID-19 pandemic, a new analysis finds, according to a FierceHealthcare
- Liminal BioSciences Announces Resubmission of Biologics License Application to FDA for Ryplazimhttps://modernod.com/news/liminal-biosciences-announces-resubmission-of-biologics-license-application-to-fda-for-ryplazim/2478254/Liminal BioSciences announced that the company, through its U.S. subsidiary Prometic Biotherapeutics, has filed a resubmission of the biologics license application (BLA) for Ryplazim (plasminogen) (Ryplazim) with the FDA for the treatment of congenital plasminogen deficiency (C-PLGD). “The
- CEO Expects Pfizer Will Know By October If COVID-19 Vaccine Workshttps://modernod.com/news/ceo-expects-pfizer-will-know-by-october-if-covid-19-vaccine-works/2478246/Pfizer CEO Albert Bourla said that late-stage study results could be available by the end of October for a coronavirus vaccine it is co-developing with BioNTech, adding “we should have enough [data]…to say whether the product works or not.” His remarks come in the wake of the Trump ad
- Alimera Sciences Announces Enrollment of First Patient in NEW DAY Clinical Trial to Evaluate Iluvien as Baseline Therapy for DMEhttps://modernod.com/news/alimera-sciences-announces-enrollment-of-first-patient-in-new-day-clinical-trial-to-evaluate-iluvien-as-baseline-therapy-for-dme/2478243/Alimera Sciences announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone ac
- EnChroma Lens Technology Addresses Low Vision and Age-Related Eye Conditionshttps://modernod.com/news/enchroma-lens-technology-addresses-low-vision-and-age-related-eye-conditions/2478241/EnChroma announced the EnChroma Lx Lens Technology, a new lens series and eyewear designed for low vision and people 50+ with glare sensitivity, to address a rapidly growing category of visual challenges worldwide. EnChroma Lx Technology is specially engineered to sup
- Sanofi, GSK Start Phase 1/2 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/sanofi-gsk-start-phase-1-2-study-of-covid-19-vaccine-candidate/2478239/Sanofi and GlaxoSmithKline announced Thursday the start of a phase 1/2 study of their experimental adjuvanted COVID-19 vaccine, with plans to move to late-stage trials this year. The companies added that in parallel, they are scaling up manufacturing of the antigen and adjuvant with the target of
- AstraZeneca Kicks Off Phase 3 Study of COVID-19 Vaccine AZD1222 in the UShttps://modernod.com/news/astrazeneca-kicks-off-phase-3-study-of-covid-19-vaccine-azd1222-in-the-us/2478229/AstraZeneca announced the start of a phase 3 study in the US investigating its experimental COVID-19 vaccine AZD1222 in up to 30,000 adults aged 18 years or over. Subjects in the trial, called D8110C00001, will be randomized to receive two doses of either AZD1222 or a saline control, 4 weeks apar
- RegeneRx Joint Venture Expects to Complete Phase 3 Dry Eye Trial in November 2020https://modernod.com/news/regenerx-joint-venture-expects-to-complete-phase-3-dry-eye-trial-in-november-2020/2478222/RegeneRx Biopharmaceuticals announced that its US joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome. According to GtreeBNT, the ARISE-3 trial was delayed a few months due to COVID-19; h
- PDL BioPharma Files With SEC For Potential Spin-Off of Lensarhttps://modernod.com/news/pdl-biopharma-announces-filing-of-a-form-10-registration-statement-with-the-sec-for-a-potential-spin-off-of-lensar-to-pdls-stockholders/2478207/PDL BioPharma announced that its majority owned medical device subsidiary, Lensar, has filed a registration statement on Form 10 with the Securities and Exchange Commission (SEC) relating to a potential spin-off of Lensar from PDL. “Preparations for a spin-off of Lensar to PDL’
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati